Effectiveness of Apixaban for Treating Portal Vein Clots More Than One Year After Laparoscopic Splenectomy

What this Trial Is About

This research aims to evaluate whether Apixaban is effective and safe for treating portal vein thrombosis that occurs more than one year after laparoscopic splenectomy in patients with cirrhosis and related conditions. The study focuses on patients who have undergone this surgery and later develop this specific type of thrombosis. The purpose is to understand how well Apixaban works in this situation and to monitor its effects on the thrombosis. Participants who develop portal vein thrombosis more than a year after their laparoscopic splenectomy will receive oral Apixaban at a dose of 2.5 mg twice daily. The response to this treatment will be assessed every three months using Doppler ultrasound or contrast-enhanced CT scans to check changes in the thrombosis. If the treatment is found to be effective, patients will continue taking Apixaban. During the study, patients will attend regular imaging assessments to monitor changes in their portal vein thrombosis. The main outcome being measured is the proportion of patients who achieve complete reopening recanalization of the thrombosed portal vein after six months or more of treatment. Partial recanalization rates will also be tracked as a secondary outcome. Participants will be followed throughout this period to assess treatment outcomes and safety, with the study expected to run until 2027.

Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS